“DELINKING:” THE FACTS

“Delinking” would saddle patients with as much as $26 billion in higher health care premiums.

Big drug companies stand to reap a windfall of more than $22 billion in increased revenues if “delinking” is imposed on the private market.

Despite Big Pharma’s claims, there is no correlation between rebates and higher drug prices.

What you can do

Join us in urging lawmakers to protect patients, employers and unions from the Big Pharma money grab: